Get started
Author

Shurui Zhou

Glutamate from nerve cells promotes perineural invasion in pancreatic cancer by regulating tumor glycolysis through HK2 mRNA-m6A modification
2022 · Fengjiao Li, Chong He, et al. · Pharmacological Research · 76
Extracellular vesicle‐packaged lncRNA from cancer‐associated fibroblasts promotes immune evasion by downregulating HLA‐A in pancreatic cancer
2024 · Hanming Yao, Chengzhi Huang, et al. · Journal of Extracellular Vesicles · 49
PDF
Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progression
2024 · Ziyi Zhong, Kege Yang, et al. · Cancer Letters · 43
CCL3 secreted by hepatocytes promotes the metastasis of intrahepatic cholangiocarcinoma by VIRMA-mediated N6-methyladenosine (m6A) modification
2023 · Shurui Zhou, Kege Yang, et al. · Journal of Translational Medicine · 27
PDF
GLUT1 Regulates the Tumor Immune Microenvironment and Promotes Tumor Metastasis in Pancreatic Adenocarcinoma via ncRNA-mediated Network
2022 · Fengjiao Li, Chong He, et al. · Journal of Cancer · 27
PDF
Storage Time of Cryopreserved Embryos and Pregnancy Outcomes: A Dose-Response Meta-Analysis
2021 · Yuanlin Ma, Xiaochen Liu, et al. · Geburtshilfe und Frauenheilkunde · 26
PDF
Glycolysis and tumor progression promoted by the m6A writer VIRMA via m6A-dependent upregulation of STRA6 in pancreatic ductal adenocarcinoma
2024 · Kege Yang, Ziyi Zhong, et al. · Cancer Letters · 23
Pancancer analysis uncovers an immunological role and prognostic value of the m6A reader IGF2BP2 in pancreatic cancer
2023 · Hui Deng, Hanming Yao, et al. · Molecular and Cellular Probes · 17
LLMs in Mobile Apps: Practices, Challenges, and Opportunities
2025 · Kimberly Hau, Safwat Hassan, et al. · IEEE/ACM International Conference on Mobile Software Engineering and Systems (MOBILESoft) · 15
PDF
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial
2025 · Jingjing Li, Shurui Zhou, et al. · Nature Communications · 14
PDF
Development and validation of a radiomics model of magnetic resonance for predicting liver metastasis in resectable pancreatic ductal adenocarcinoma patients
2023 · Yuzhou Huang, Shurui Zhou, et al. · Radiation Oncology · 14
PDF
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers
2025 · Jiaojiao Ni, Chaoqun Li, et al. · BMC Medicine · 11
PDF
How to Sustain a Scientific Open-Source Software Ecosystem: Learning from the Astropy Project
2024 · Sun, Jiayi, Patil, Aarya, et al. · arXiv (Cornell University) · 6
PDF
Hydroxyl safflower yellow A regulates bone-fat balance in osteoporosis by SphK1/S1P/S1PR signaling pathway
2025 · Xuefeng Xu, Xin Hu, et al. · Biochemical Pharmacology · 5
Aligning Documentation and Q&A Forum through Constrained Decoding with Weak Supervision
2023 · Rohith Pudari, Shiyuan Zhou, et al. · IEEE International Conference on Software Maintenance (ICSM) · 4
Cancer-specific survival in patients with cholangiocarcinoma after radical surgery: a Novel, dynamic nomogram based on clinicopathological features and serum markers
2023 · Shurui Zhou, Yue Zhao, et al. · BMC Cancer · 4
PDF
Gastric cancer nodal tumour-stroma ratios influence prognosis.
2020 · J Huang, B Yang, et al. · PubMed Central · 4
PDF
Can We Do Better with What We Have Done? Unveiling the Potential of ML Pipeline in Notebooks
2024 · Yuangan Zou, Xinpeng Shan, et al. · IEEE International Conference on Software Maintenance (ICSM) · 2
First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial.
2025 · Jieer Ying, Qi Xu, et al. · Journal of Clinical Oncology · 1
PDF
Puerarin attenuates inflammatory progression in atherosclerosis by inhibiting NLRP3 inflammasome activation via the SphK1/S1P/S1PR1 axis
2026 · Yaru Zhao, Faxin Fan, et al. · Journal of Holistic Integrative Pharmacy
Exploratory genomic stratification of benefit from first-line immunotherapy-based combination in advanced biliary tract cancer: a biomarker analysis of a randomized phase 2 trial
2026 · Yatong He, Zeyu Ruan, et al. · Frontiers in Immunology
PDF
Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: A multicenter, open-label phase II trial
2026 · Qi Xu, Shurui Zhou, et al. · Journal of Hepatology
PDF
Works count: 22
Citation count: 368
H-index: 11
I10-index: 12
Year
Topic
Type